The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
Main Authors: | , , , , , , , |
---|---|
格式: | Conference item |
出版: |
Wiley
2018
|
Main Authors: | , , , , , , , |
---|---|
格式: | Conference item |
出版: |
Wiley
2018
|